Compare NRIM & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRIM | VALN |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.6M | 582.2M |
| IPO Year | 2002 | 2021 |
| Metric | NRIM | VALN |
|---|---|---|
| Price | $22.71 | $5.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $28.33 | $12.28 |
| AVG Volume (30 Days) | ★ 115.9K | 9.9K |
| Earning Date | 10-15-2026 | 11-24-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $255,581,000.00 | N/A |
| Revenue This Year | $1.76 | N/A |
| Revenue Next Year | $25.33 | $87.84 |
| P/E Ratio | $11.82 | ★ N/A |
| Revenue Growth | ★ 30.43 | N/A |
| 52 Week Low | $21.94 | $4.75 |
| 52 Week High | $30.82 | $12.18 |
| Indicator | NRIM | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 37.14 |
| Support Level | N/A | $4.75 |
| Resistance Level | $25.33 | $5.52 |
| Average True Range (ATR) | 0.59 | 0.21 |
| MACD | -0.10 | -0.03 |
| Stochastic Oscillator | 16.88 | 0.00 |
Northrim BanCorp Inc is a bank holding company operating through three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. The Community Banking segment, which generates the majority of revenue, provides loan and deposit products to business and consumer customers in its market areas. The Home Mortgage Lending segment focuses on the origination and sale of mortgage loans for one-to-four family residential properties, mortgage loan servicing for certain loans sold, and investment in selected residential mortgage loans. The Specialty Finance segment provides factoring, asset-based lending, and alternative working capital solutions to small and medium-sized enterprises and includes SCF and Northrim Funding Services.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.